Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT01829113 - Apatorsen + Carboplatin + Pemetrexed vs Carboplatin + Pemetrexed & Non Squamous Non-small-cell lung carcinoma (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

A randomized, double-blinded, multicenter phase II trial to study treating previously untreated patients with metastatic Non Squamous Non-small-cell lung carcinoma (NSCLC)

Primary outcome measures:
Progression-free survival (PFS)

The authors concluded that adding apatorsen to carboplatin and pemetrexed was well tolerated but did not improve outcomes in patients with metastatic non squamous NSCLC cancer in the ﬁrst-line setting.
Spigel et al. 2019…

References (Sources)

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
Spigel et al. 2019

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

NCT01829113 - Apatorsen + Carboplatin + Pemetrexed vs Carboplatin + Pemetrexed & Non Squamous Non-small-cell lung carcinoma (NSCLC)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links